AB Klaipėdos nafta unaudited financial information for 2022
AB Klaipėdos nafta (hereinafter – KN, the Company) announces the unaudited consolidated (hereinafter – the Group) and separate financial results for 2022.
Key financial indicators:
|Net profit (loss)||(5.5)||(64.0)||(6.3)||(64.9)|
|Adjusted net profit (loss)||9.3||(47.2)||8.5||(48.1)|
Revenue from oil terminals for 2022 amounts to EUR 27.8 million and is higher by 29.9% compared to 2021 (EUR 21.4 million). The increase of revenue was due to 16.9% or 616 thousand tones higher transhipment of oil products. Transhipment quantities in the Company's oil terminals were affected by continuous initiatives to explore new transhipment routes which allowed KN to become a part of the logistics chain of fuel supply to new customers in southwest directions. Also, in 2022 KN oil terminal was in demand as oil products import hub, notably fuel oil, which – in response to all-time highs of gas prices - was used as alternative heating generation fuel source in Vilnius city heating infrastructure at the start of the winter season of 2022.
Regulated LNG activities revenue for 2022 reached EUR 44.6 million and is higher by EUR 9.8 million or 28.2% compared to 2021 (EUR 34.8 million). The main reasons: (1) higher regasification revenue by EUR 26.7 million due to increased demand and regasification tariff from 0.41 EUR/MWh to 1.19 EUR/MWh; (2) received revenue related to the natural gas consumer’s liability for previous periods after the court decision in amount of EUR 1.1 million; (3) higher revenue from AB Amber Grid by EUR 0.5 million due to recalculated actual consumption capacities of previous period (2022 – EUR 1.1 million, 2021 – EUR 0.6 million); (4) lower revenue from the fixed part of LNG regasification service fee by EUR 18.5 million due to implemented LNG terminal capacity allocation and tariffication model when KN part in security supplement from May 2022 was decreased to 0 EUR/MWh/day/year.
Revenue from commercial LNG activities for 2022 amounts to EUR 5.4 million and is lower by 3.5% compared to 2021 (EUR 5.6 million). Commercial LNG activities consist of business development projects including LNG terminal operator services provided at the Port of Açu terminal in Brazil and LNG reloading station in Klaipėda.
During 2022, the same as during 2021, the Group‘s and the Company‘s net profit (loss) was significantly affected by unrealized currency exchange losses and by the reduction of LNG security supplement from 1 January 2020 by EUR 26.8 million per annum. The unrealized impact of exchange rates arose from the 1 January 2019 under the requirements of IFRS 16 “Lease”, according to which the Company recognizes finance lease obligations and the major part of them is denominated in US dollars. Whereas all US dollar denominated lease liabilities relate to LNG terminal, the effect of unrealized exchange rate is reflected in the regulated segment.
- Condensed Consolidated and Separate Financial Statements of AB Klaipėdos nafta for 2022.
- Presentation of the unaudited financial results of the Group for 2022.
Mindaugas Kvekšas, Chief Financial Officer, +370 46 391772
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
CFO Martin Klöti to leave Schweiter Technologies29.3.2023 06:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR CFO Martin Klöti to leave Schweiter Technologies Martin Klöti, Chief Financial Officer (CFO) and member of the Management of Schweiter Technologies, has decided to leave the company Steinhausen, 29 March 2023 – Martin Klöti, who has been with Schweiter Technologies since 2003 and CFO of the Group since 2014, has decided to leave the Management as of September 2023 to take up a new position outside the company. The Board of Directors will be sorry to see him leave and wishes to take this opportunity to thank him for his many years of dedicated service and his enormous contribution to the development of Schweiter Technologies. The search for his successor will be initiated forthwith. For further information please contact: Martin Klöti, CFO Tel. +41 41 757 77 00 email@example.com ABOUT SCHWEITER Schweiter Technologies, with its head office in Steinhausen, Switzerland, is a globally active Group focusing on composites solutions with its divi
Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia29.3.2023 05:39:38 CEST | Press release
-- The two parties will collaborate to develop and commercialize toripalimab in 9 Southeast Asian countries through a joint venture company, Excellmab -- Excellmab will be responsible for the development, medical affairs, production of finished products, and commercialization of toripalimab within the cooperation territory. The profits available for distribution by Excellmab will be distributed in proportion to the respective shareholdings of the parties -- Using the Excellmab platform, the two parties also plan to collaborate extensively to introduce more high-quality innovative drugs into Southeast Asian markets to achieve joint and long-term development -- According to the progress of toripalimab’s R&D and other projects, Junshi Biosciences may receive a milestone payment of up to approximately US$4.52 million, plus a certain percentage of royalties on net sales SHANGHAI, China and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Bioscience
Aduro Clean Technologies Increases Size of Private Placement to $4 Million29.3.2023 02:12:40 CEST | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SARNIA, Ontario, March 28, 2023 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQB: ACTHF) (FSE: 9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics, and to transform heavy crude and renewable oils into feedstocks and higher-value fuels, is pleased to announce that, further to its news release dated March 8, 2023, it has increased the size of its non-brokered private placement of units (the “Units”) at $0.93 per Unit for gross proceeds of a minimum of $1,999,965 and up to a maximum of $4,000,000 (the “LIFE Offering”). Each Unit will consist of one (1) common share in the capital of the Company (each, a “Common Share”) and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable into one (1) Common Share (each, a “Warrant Share”) at a price o
ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform28.3.2023 22:05:00 CEST | Press release
SOLANA BEACH, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance. “This invention will help clinicians guide the delivery of biologic therapies — from stem cell transplants to gene therapy vectors — to specific locations in the human brain with real-time image guidance,” said Dr. Daniel Lim, MD, PhD, Professor of Neurological Surgery at UCSF. “By helping surgeons tailor biologic delivery to individual patient anatomy and specific diseases, I hope that this invention can contribute importantly to the successful treatment of neurological disor
Development of the Annual General Meeting of the BANK of Greenland28.3.2023 22:03:19 CEST | Press release
Minutes of General Meeting To Nasdaq OMX Copenhagen 28 March 2022 Company announcement no. 05/2023 Development of the Annual General Meeting of the BANK of Greenland Today, the BANK of Greenland held its Annual General Meeting in accordance with the Articles of Association and the previously published notice convening the meeting. The Annual General Meeting was attended by shareholders representing 1,049,468 votes, of which 612,498 votes were given by proxy to the Board of Directors, 62,821 votes were covered by instructions to holders of power of attorney and 115,455 votes of correspondance. The Board of Directors' Report on the Bank's activities during the past year The Chairman of the Board of Directors Gunnar í Liða presented the Board of Directors' report on the Bank's activities during the past year. The report of the Board of Directors was noted. The Chairman's report can be viewed on the Bank's website at www.banken.gl. The minutes of the Annual General Meeting will also be pub